These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1806612)

  • 1. Evaluation of a repeatable depot-bromocriptine preparation(Parlodel LAR) for the treatment of acromegaly.
    Plöckinger U; Quabbe HJ
    J Endocrinol Invest; 1991 Dec; 14(11):943-8. PubMed ID: 1806612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment of acromegalic patients with repeatable parenteral depot-bromocriptine.
    Jaspers C; Haase R; Pfingsten H; Benker G; Reinwein D
    Clin Investig; 1993 Jul; 71(7):547-51. PubMed ID: 8374248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of different dopaminergic agents in the treatment of acromegaly.
    Colao A; Ferone D; Marzullo P; Di Sarno A; Cerbone G; Sarnacchiaro F; Cirillo S; Merola B; Lombardi G
    J Clin Endocrinol Metab; 1997 Feb; 82(2):518-23. PubMed ID: 9024247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Results of treatment for acromegaly with long-acting bromocriptine (Parlodel LAR)].
    Bednarek-Tupikowska G; Bohdanowicz-Pawlak A; Bolanowski M; Jedrzejak J; Milewicz A
    Endokrynol Pol; 1993; 44(2):161-8. PubMed ID: 8055787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depot-bromocriptine treatment for prolactinomas and acromegaly.
    Grossman A; Ross R; Wass JA; Besser GM
    Clin Endocrinol (Oxf); 1986 Feb; 24(2):231-8. PubMed ID: 3708874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
    Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
    Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma growth hormone suppressive effect of bromocriptine in acromegaly. Evaluation by plasma GH day profiles and plasma GH concentrations during oral glucose tolerance tests.
    Nortier JW; Croughs RJ; Thijssen JH; Schwarz F
    Clin Endocrinol (Oxf); 1984 May; 20(5):565-71. PubMed ID: 6744634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bromocriptine therapy in acromegaly. A long-term review of 35 cases.
    Sachdev Y; Gopal K; Garg VK
    Postgrad Med J; 1981 Apr; 57(666):210-6. PubMed ID: 7027229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
    Tsagarakis S; Tsiganou E; Tzavara I; Nikolou H; Thalassinos N
    Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
    Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.
    Colao A; Marzullo P; Ferone D; Spinelli L; Cuocolo A; Bonaduce D; Salvatore M; Boerlin V; Lancranjan I; Lombardi G
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3132-40. PubMed ID: 10999798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine.
    Ciccarelli E; Miola C; Grottoli S; Avataneo T; Lancranjan I; Camanni F
    J Clin Endocrinol Metab; 1993 Feb; 76(2):484-8. PubMed ID: 8432794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
    Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bromocriptine reduces growth hormone in acromegaly.
    Bell PM; Atkinson AB; Hadden DR; Kennedy L; Leslie H; Merrett JD; Sheridan B
    Arch Intern Med; 1986 Jun; 146(6):1145-9. PubMed ID: 3718102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of bromocriptine on insulin secretion and glucose tolerance in patients with acromegaly.
    Feek CM; Bevan JS; Taylor S; Brown NS; Baird JD
    Clin Endocrinol (Oxf); 1981 Nov; 15(5):473-8. PubMed ID: 7035013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
    Turner HE; Thornton-Jones VA; Wass JA
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral prednisolone supplement abolishes the acute adverse effects following initiation of depot bromocriptine therapy.
    Jenkins PJ; Jain A; Jones SL; Besser GM; Grossman AB
    Clin Endocrinol (Oxf); 1996 Oct; 45(4):447-51. PubMed ID: 8959084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases.
    Beckers A; Petrossians P; Abs R; Flandroy P; Stadnik T; de Longueville M; Lancranjan I; Stevenaert A
    J Clin Endocrinol Metab; 1992 Jul; 75(1):275-80. PubMed ID: 1619019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.